NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
10 September 2024
| Name: | OSTEOPORE LIMITED (OSX) |
| ISIN: | AU0000053324 |
| Date of Listing: | 23 September 2019 |
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 630 538 957ABN: 65 630 538 957
Registration Date: 11 December 2018
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
Automic Registry Pty Ltd
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Osteopore Limited will be lifted from the commencement of trading on Wednesday, 17 April 2024 following lodgement of its Annual Report for the year ended 31 December 2023. | 16/04/2024 |
The company lodges its Annual Report to Shareholders. | 16/04/2024 |
The company releases its Appendix 4G and Corporate Governance Statement. | 16/04/2024 |
The company releases a response to ASX Query Letter. | 15/04/2024 |
The maturity date of the Bridging Loan was ninety calendar days from the disbursement date. The Company has entered a variation deed on 9 April 2024 with the Lender to extend the maturity date of the Bridging Loan to 1 May 2025. The Bridging Loan interest rate under the Variation Deed has changed from 3% per month in the initial three months, 4% per month in the fourth month and 5% per month in the fifth month and thereafter, to 3% per month calculated on a daily rest basis and payable on the first business day of each month. Notwithstanding any other provisions to the Variation Deed, the Company has the option to make early repayments to the Bridging Loan at any time. Other Bridging Loan terms and conditions remain unchanged. | 10/04/2024 |
The company's AGM will be held on 30 May 2024. Any nominations for directors must be received at the company's registered office no later than 5:00pm (WST) on 18 April 2024. | 08/04/2024 |
The company's AGM will be held on 30 May 2024. Any nominations for directors must be received at the company's registered office no later than 5:00pm (WST) on 18 April 2024. | 08/04/2024 |
The company releases an updated notice of proposed issue of securities. | 05/04/2024 |
The Renounceable Pro-Rata Entitlement Offer and Shortfall Offer to raise ~A$3,000,000 (before costs) closed on 2 April 2024 with strong support from eligible shareholders. | 05/04/2024 |
The company releases an updated notice of proposed issue of securities. | 04/04/2024 |
The company releases a replacement prospectus for Renounceable Rights Issue. | 04/04/2024 |
The company releases a notice of proposed issue of securities. | 02/04/2024 |
The company releases a letter to its eligible shareholders regarding the entitlement offer. | 02/04/2024 |
The Company releases a replacement entitlement offer prospectus for a renounceable pro rata offer to Eligible Shareholders of approximately 103,286,890 New Shares at an issue price of $0.029 per New Share on the basis of 10 New Share for every 1 Existing Shares with 1 free attaching New Option for every 5 New Shares acquired to raise up to $3,000,000 before costs. This Prospectus is also being issued for the Shortfall Offer described in this Prospectus. | 02/04/2024 |
The securities of the Company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 2 April 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 28 March 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 02/04/2024 |
The securities of the Company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 2 April 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 28 March 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 02/04/2024 |
The securities of Osteopore Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OSX, pending the release of its Annual Report. | 28/03/2024 |
The suspension of the following options of Osteopore Limited ("˜will be lifted immediately following ASX being satisfied that there is a sufficient spread of option holders for the purposes of Listing Rule 2.5 condition 6: OSXO | 26/04/2023 |
The following Options of Osteopore Limited will be suspended from quotation immediately under Listing Rule 17.3: OSXO. | 24/04/2023 |
The suspension of trading in the securities of Osteopore Limited will be lifted immediately following the release by OSX of an announcement regarding a capital raising. | 22/12/2022 |
The company releases a notice of proposed issue of securities. | 22/12/2022 |
Osteopore has received binding commitments from sophisticated and existing investors for a total A$1,000,000 Placement at $0.15 per share, with one (1) free attaching option for every one (1) new share subscribed for. Proceeds from the Placement will be used to support sales momentum, develop and launch new breakthrough products, secure regulatory clearances in new markets and provide capacity for continued exploration of potential partnerships and acquisition opportunities aimed at increasing company value. The Company has entered into a non-binding term sheet with Mr Lim Jae Hoon for the proposed acquisition of 100% of the businesses owned by Lomic Korea Co., Ltd, 3D Aesthetic Solutions Pte Ltd, 3D Healthcare Solutions Co., Ltd and 3D Aesthetic Medical Equipment and Supplies Trading in order to increase the distribution of Osteopore products. | 22/12/2022 |
The securities of Osteopore Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OSX, pending the release of an announcement regarding a capital raising. | 21/12/2022 |
listed entity carried for record purposes only | 23/09/2019 |
The suspension of trading in the securities of Osteopore Limited will be lifted from the commencement of trading on Wednesday, 17 April 2024 following lodgement of its Annual Report for the year ended 31 December 2023. | 16/04/2024 |
The company lodges its Annual Report to Shareholders. | 16/04/2024 |
The company releases its Appendix 4G and Corporate Governance Statement. | 16/04/2024 |
The company releases a response to ASX Query Letter. | 15/04/2024 |
The maturity date of the Bridging Loan was ninety calendar days from the disbursement date. The Company has entered a variation deed on 9 April 2024 with the Lender to extend the maturity date of the Bridging Loan to 1 May 2025. The Bridging Loan interest rate under the Variation Deed has changed from 3% per month in the initial three months, 4% per month in the fourth month and 5% per month in the fifth month and thereafter, to 3% per month calculated on a daily rest basis and payable on the first business day of each month. Notwithstanding any other provisions to the Variation Deed, the Company has the option to make early repayments to the Bridging Loan at any time. Other Bridging Loan terms and conditions remain unchanged. | 10/04/2024 |
The company's AGM will be held on 30 May 2024. Any nominations for directors must be received at the company's registered office no later than 5:00pm (WST) on 18 April 2024. | 08/04/2024 |
The company's AGM will be held on 30 May 2024. Any nominations for directors must be received at the company's registered office no later than 5:00pm (WST) on 18 April 2024. | 08/04/2024 |
The company releases an updated notice of proposed issue of securities. | 05/04/2024 |
The Renounceable Pro-Rata Entitlement Offer and Shortfall Offer to raise ~A$3,000,000 (before costs) closed on 2 April 2024 with strong support from eligible shareholders. | 05/04/2024 |
The company releases an updated notice of proposed issue of securities. | 04/04/2024 |
The company releases a replacement prospectus for Renounceable Rights Issue. | 04/04/2024 |
The company releases a notice of proposed issue of securities. | 02/04/2024 |
The company releases a letter to its eligible shareholders regarding the entitlement offer. | 02/04/2024 |
The Company releases a replacement entitlement offer prospectus for a renounceable pro rata offer to Eligible Shareholders of approximately 103,286,890 New Shares at an issue price of $0.029 per New Share on the basis of 10 New Share for every 1 Existing Shares with 1 free attaching New Option for every 5 New Shares acquired to raise up to $3,000,000 before costs. This Prospectus is also being issued for the Shortfall Offer described in this Prospectus. | 02/04/2024 |
The securities of the Company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 2 April 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 28 March 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 02/04/2024 |
The securities of the Company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 2 April 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 28 March 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 02/04/2024 |
The securities of Osteopore Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OSX, pending the release of its Annual Report. | 28/03/2024 |
The suspension of the following options of Osteopore Limited ("˜will be lifted immediately following ASX being satisfied that there is a sufficient spread of option holders for the purposes of Listing Rule 2.5 condition 6: OSXO | 26/04/2023 |
The following Options of Osteopore Limited will be suspended from quotation immediately under Listing Rule 17.3: OSXO. | 24/04/2023 |
The suspension of trading in the securities of Osteopore Limited will be lifted immediately following the release by OSX of an announcement regarding a capital raising. | 22/12/2022 |
The company releases a notice of proposed issue of securities. | 22/12/2022 |
Osteopore has received binding commitments from sophisticated and existing investors for a total A$1,000,000 Placement at $0.15 per share, with one (1) free attaching option for every one (1) new share subscribed for. Proceeds from the Placement will be used to support sales momentum, develop and launch new breakthrough products, secure regulatory clearances in new markets and provide capacity for continued exploration of potential partnerships and acquisition opportunities aimed at increasing company value. The Company has entered into a non-binding term sheet with Mr Lim Jae Hoon for the proposed acquisition of 100% of the businesses owned by Lomic Korea Co., Ltd, 3D Aesthetic Solutions Pte Ltd, 3D Healthcare Solutions Co., Ltd and 3D Aesthetic Medical Equipment and Supplies Trading in order to increase the distribution of Osteopore products. | 22/12/2022 |
The securities of Osteopore Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OSX, pending the release of an announcement regarding a capital raising. | 21/12/2022 |
listed entity carried for record purposes only | 23/09/2019 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 04/07/2023 | Mark Leong | 325,000 | $0.049 | $15,939 |
| 30/06/2022 | Mark Leong | 150,000 | $0.106 | $15,850 |
| 10/06/2022 | Swee Hin Teoh | 100,000 | $0.155 | $15,541 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Mark Leong | Executive Chairman, Independent Director | 02/08/2021 |
| Lim Jing | CEO | 01/05/2022 |
| Daniel Ow | Independent Director | 08/10/2021 |
| Swee Hin Teoh | Non Exec Director | 23/09/2019 |
| Michael Keenan | Non Exec Director | 18/07/2023 |
| Jack Rosagro | Company Secretary | 20/05/2024 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Kellie Davis | Company Secretary | 20/05/2024 | |
| Khoon Seng Goh | CEO | 23/09/2019 | 13/07/2023 |
| Vlado Bosanac | Independent Director | 29/12/2021 | 14/02/2022 |
| Carl Runde | CFO | 02/11/2020 | 18/01/2022 |
| Stuart Carmichael | Non Exec Director | 23/09/2019 | 07/10/2021 |
| Geoff Pocock | Non Exec Director | 23/09/2019 | 07/10/2021 |
| Brett Sandercock | Non Exec Chairman | 23/09/2019 | 01/08/2021 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
